BMRN Q2 2022 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$534M+6.4% YoY

Gross Profit

$411M76.9% margin

Operating Income

$39M7.3% margin

Net Income

$28M5.2% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$56M

Free Cash Flow

$28M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$6.1B

Total Liabilities

$1.6B

Stockholders' Equity

$4.5B

Cash & Equivalents

$620M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$534M	$502M	+6.4%
Gross Profit	$411M	$375M	+9.6%
Operating Income	$39M	$12M	+235.4%
Net Income	$28M	$13M	+113.8%

Revenue Segments

Product

$518M97%

Royalty And Other

$16M3%